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Abstract
A 39-year-old patient with hypertension and a 28-year history of type 1 diabetes with numerous complications in the 
form of microangiopathy and macroangiopathy was admitted to the Cardiology Clinic due to recurrent angina pectoris 
accompanied by the intensification of ischemic electrocardiographic (ECG) changes and symptoms of heart failure. In 
addition, a history of hyperlipidemia, chronic kidney disease, Graves’ disease at euthyroid stage.
On admission, the patient hemodynamically stable, arterial pressure — 129/75 mm Hg, regular heart rate, without 
signs of losses in the pulmonary circulation, visible swelling of the lower limbs and trophic changes on the lower shink. 
In laboratory tests, mildly impaired renal function (glomerular filtration 56 ml/min), high blood glucose values (up to 
350 mg/dL), glycated hemoglobin 8.7%, hypercholesterolemia. The echocardiographic study showed a worsening of 
the left ventricular systolic function compared to the previous assessment — a decrease in ejection fraction from 46 to 
35%, on ECG — left anterior hemiblock, features of past and anterior wall infarction.
During hospitalization, the therapy of coronary heart disease, hypertension (ramipril, bisoprolol, spironolactone, and 
furosemide), diabetes (insulin initially used at a variable flow pump, followed by intensive insulin therapy and hyperlipid-
emia was modified), obtaining satisfactory results in relation to the initial ones. Extended release nitrates were included, 
and antiplatelet treatment with ticagrelor was continued. Due to elevated cholesterol, the dose of atorvastatin was 
increased. In case of therapy failure, the PCSK9 inhibitor (evolucumab) and family diagnosis of hypercholesterolemia 
were considered.
Despite the treatment, angina ailments increased, the ECG performed during the pain revealed ischemic lesions. By 
decision of the Heart Team, the patient was qualified for accelerated surgery for myocardial revascularization.
Key words: young patient, type 1 diabetes, dyslipidemia, arterial hypertension, comorbidities
Folia Cardiologica 2021; 16, 2: 142–144
Introduction
Arterial hypertension, diabetes, coronary artery disease 
and hyperlipidemia, known as diseases of affluence, are 
a growing problem in medical practice. In the context of 
diagnosis, treatment and prevention of complications, the 
occurrence of many overlapping diseases is a particularly 
difficult challenge which both the doctor and the patient 
must face. Usually, the lack of a satisfactory therapeutic 
effect is a consequence of failure to follow recommenda-
tions, which, especially when combined with the treatment 
that does not comply with the latest guidelines and lack 
of cooperation at the doctor-patient level, can lead to 
disastrous health consequences even at an early age [1].
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The therapy of ischemic heart disease, arterial hyper-
tension, hyperlipidemia, and diabetes was modified during 
hospitalization, obtaining satisfactory results compared to 
the initial ones. Medications used: ticagrelor 2 × 90 mg, 
acetylsalicylic acid (ASA) 1 × 75 mg, ramipril 1 × 5 mg, bi-
soprolol 1 × 10 mg, ivabradine 2 × 7.5 mg, spironolactone 
1 × 25 mg, atorvastatin 1 × 40 mg, furosemide 1 × 1 am-
poule (administered intravenously). Long-acting nitrates 
were added, and the antiplatelet therapy with ticagrelor 
was continued. In the case of the diabetes treatment, in-
sulin in a variable flow pump was initially applied, followed 
by intensive insulin therapy (insulin glulisine and glargine), 
gradually achieving satisfactory blood glucose values and 
a decrease of HbA1c up to 8.7%. Despite the therapy with 
atorvastatin, high levels of LDL-cholesterol and TG were 
noted. The dose of statin was increased to 80 mg and 
ezetimibe was added to the therapy. In case of failure, 
proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor 
(evolocumab) and diagnosis for familial hypercholesterol-
emia were considered.
In spite of pharmacotherapy, angina complaints were 
recurring. Echocardiography performed during the chest 
pain revealed that ischemic lesions above the anterior 
wall were found to be worse (negative T wave in leads 
V2–V4). By decision of the patient’s cardiologist, the 
patient had been qualified for an expedited surgical 
procedure of myocardial revascularization, which was 
performed in the Cardiac Surgery Department of the 
University Hospital.
Discussion
According to the 2019 European Society of Cardiology (ESC) 
guidelines, a patient suffering from type 1 diabetes (lasting 
over 20 years) with numerous complications, cardiovascu-
lar disease, hypercholesterolemia and arterial hypertension 
is classified as an extreme high-risk cardiovascular patient 
despite their young age. In this group, special attention is 
paid to the necessity of tight blood glucose control; the 
recommended HbA1c level is < 6.5% [2], the blood pressure 
should be reduced to < 130 and < 80 mm Hg for systolic 
and diastolic arterial blood pressure respectively [3].
In the group of extreme high cardiovascular risk, during 
secondary prevention, the recommended target value for 
LDL is to reduce it by 50% and reach the LDL target value 
≤ 55 mg/dL. A special group should be identified (patients 
who have had a second cardiovascular event associated 
with atherosclerosis within the last two years while taking 
the maximum, tolerable dose of statin) — a reduction of 
LDL < 40 mg/dL may be considered among these patients. 
In the case of a maximum dose of statin with a lack of sat-
isfactory therapeutic effect it is justified to include ezeti-
mibe, followed by PCSK9 inhibitors.
Case report
A 39-year-old patient was admitted to the Clinic of Cardi-
ology because of recurrent angina complaints, ischemic 
changes in electrocardiogram (ECG) and symptoms of 
heart failure in the form of exercise-induced dyspnea [New 
York Heart Association (NYHA II)]. Medical history: stable 
coronary artery disease [Canadian Cardiovascular Society 
(CCS II)], long-term uncontrolled arterial hypertension, 
28-year history of poorly controlled type 1 diabetes treated 
using the intensive insulin therapy regimen [maximum 
value of glycated hemoglobin (HbA1c) 14.8%, blood glucose 
values up to 350 mg/dL), with complications — microan-
giopathy (diabetic retinopathy — status post-surgery for 
retinal detachment of the left eye, diabetic nephropathy, di-
abetic polyneuropathy) and macroangiopathy (2013 — right 
lower leg amputation due to non-healing neuroischaemic 
ulcer), past myocardial infarction (three times), numerous 
percutaneous coronary interventions [2010 — anterior wall 
myocardial infarction [anterior ST-elevation myocardial 
infarction (STEMI) treated with percutaneous coronary 
intervention (PCI) of the left anterior descending together 
with drug-eluting stent (DES) implantation; October 2016 
— re-angioplasty of a left anterior descending, two DES 
implantation, November 2016 — anterior STEMI due to 
stent thrombosis, thrombectomy and PCI of a left anterior 
descending with implantation of another DES]. In addition, 
combined hyperlipidemia, chronic kidney disease [stage 
G3a acc. to Kidney Disease Improving Global Outcomes 
(KDIGO 2012)], Graves’ disease (currently in the stage 
of euthyreosis; previously treated with thiamazole). The 
patient was under the care of a diabetology and cardiology 
clinic. The patient was treated pharmacologically on a reg-
ular basis. It should be added that the patient’s passive 
attitude during the treatment process and his negative 
attitude towards therapeutic decisions raise doubts as to 
the patient’s compliance with recommendations.
On admission to the hospital, the patient was hemo-
dynamically, cardiovascularly and respiratorily stable, fully 
conscious and verbally responsive. Physical examination: 
regular cardiac activity, no signs of pulmonary hemostasis, 
swelling of the lower limbs and trophic lesions of the lower 
legs. Arterial blood pressure — 129/75 mm Hg, heart rate 
— 98/min. Laboratory tests: kidney failure [glomerular fil-
tration rate (GFR) 56 mL/min], HbA1c — maximum values 
in the medical history, i.e. 14.8%, combined hyperlipid-
emia [total cholesterol 365 md/dL, low-density lipoprote-
ins (LDL) 259 mg/dL, triglycerides (TG) 223 mg/dL]. ECG: 
sinus rhythm — 66/min., left anterior hemiblock (LAH), and 
signs of the past anterior and inferior wall myocardial in-
farction. Echocardiography: deterioration of left ventricular 
systolic function compared to the previous evaluation (April 
2017) — ejection fraction (EF) decrease from 46% to 35%.
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scientific societies concerning effective treatment of par-
ticular disease entities is not without significance either.
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Furthermore, in such patients, special attention is 
paid to the appropriateness of prolonged dual antiplate-
let therapy to prevent cardiovascular events. It should be 
remembered that the coexistence of diabetes and vascu-
lar diseases of the lower extremities increases the risk of 
limb amputation by 5 times, and this risk increases with 
the duration of the disease.
The ESC 2019 guidelines for the diagnosis and treat-
ment of chronic coronary syndromes indicate the benefits 
of combination therapy (ASA + rivaroxaban) in patients 
with chronic coronary syndromes, diabetes, and periph-
eral artery disease (PAD) [4]. In the COMPASS (Cardiova-
scular Outcomes for People Using Anticoagulation Stra-
tegies) trial, the use of such therapy was associated with 
a reduction in the number of ischemic events compared 
to ASA monotherapy. Particularly high reduction of cardio-
vascular risk was observed in patients with diabetes, PAD, 
moderate chronic kidney disease, i.e. in those like the pa-
tient in question [5].
The procedure described above will reduce the preva-
lence rate of adverse cardiovascular events. The problem 
is the lack of certainty regarding the continuity of treat-
ment in outpatient conditions, especially that the percen-
tage of patients with chronic diseases that do not comply 
with medical recommendations is estimated to be as high 
as 60% [1]. To achieve therapeutic success, the necessity 
of applying the model of doctor-patient equivalence, whe-
re the level of adherence to medical recommendations 
is increased by the patient’s active participation in the 
therapeutic process, is increasingly emphasized [6]. The 
necessity for doctors to follow the recommendations of 
